ArticleCancer discovery2018
TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 160 citations in OpenAlex.
- Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant.Pediatric blood & cancer · 2026Article
- Different primary thyroid B-cell lymphomas show overlapping mutation profiles, suggesting involvement of a common pathogenic process.Haematologica · 2026Article
- Epigenetic regulation of B cell tolerance and dysfunction in autoimmune disease.Nature reviews. Immunology · 2026Review
- B cell TET2 recruits OGT for nuclear TET2 and H2B O-GlcNAcylation to drive AID and BLIMP-1 expression and maturation of the antibody response.Cell reports · 2026Article
- AID and TET2 cooperate to demethylate Irf4 for plasma cell fate in germinal center B cells.The Journal of experimental medicine · 2026Article
- Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma.Blood neoplasia · 2026Article
- Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes.Annual review of cancer biology · 2026Article
- Methylome and Transcriptome Analysis Reveals Differences in Callus Development and Plantlet Regeneration Capacity Between TwoPlants (Basel, Switzerland) · 2026Article
- Epigenetic dysregulation of B‑cells in autoimmune diseases and lymphomas (Review).International journal of molecular medicine · 2026Review
- Mouse models of B cell lymphomas on the basis of genetic features.Frontiers in immunology · 2026Review
- miR-155 aberrant expression impairs tumor rejection because of its targeting of ICOSL and multiple pathways implicated in the antitumor response.Pharmacological reviews · 2026Review
- Article
- T follicular helper cells transiently unlock a plasticity state in germinal centre B cells during the humoral immune response.Nature cell biology · 2026Article
- Case Report: longitudinal immunoglobulin abnormalities preceding IgA-λ MGUS and colonic DLBCL: a case suggesting immune-driven B-cell dysregulation.Frontiers in oncology · 2026Article
- Identification of 5mC regulatory factors mediating methylation patterns and prognosis models in head and neck squamous cell carcinoma.Discover oncology · 2025Article
- RNA NExperimental & molecular medicine · 2025Article
- In vivo CRISPR screening reveals cooperation of KMT2D and TP53 deficiencies in B-cell lymphomagenesis.Blood advances · 2025Article
- The TET protein family interactor PROSER1 sustains hematopoietic stem cell function.Blood advances · 2025Article
- Ten-Eleven Translocation Family Proteins: Structure, Biological Functions, Diseases, and Targeted Therapy.MedComm · 2025Review
- Biomolecular condensates in immune cell fate.Nature reviews. Immunology · 2025Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
34 authors at 9 institutions in 2 countries.
Pilar M Dominguez *Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.
Hussein Ghamlouch *INSERM U1170, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Wojciech Rosikiewicz *The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
Parveen KumarThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
Wendy BéguelinDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.
Lorena FontánDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-1021-3654
Martín A RivasDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-9603-6897
Patrycja PawlikowskaCNRS UMR8200, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Marine ArmandINSERM U1170, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Enguerran MoulyINSERM U1170, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Miguel Torres-MartinSylvester Comprehensive Cancer Center, Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, Florida.
Ashley S DoaneDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-1489-1786
María T Calvo FernandezDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-2583-2199
Matt DurantDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-9415-1659
Veronique Della-ValleINSERM U1170, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Matt TeaterDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-9415-1659
Luisa CimminoDepartment of Pathology, Laura and Isaac Perlmutter Cancer Center, and The Helen L. and Martin S. Kimmel Center for Stem Cell Biology, NYU School of Medicine, New York, New York.
Nathalie DroinINSERM U1170, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Saber TadrosDepartment of Lymphoma/Myeloma and Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Samaneh MotanaghDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
Alan H ShihCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark A RubinDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-8321-9950
Wayne TamPathology and Laboratory Medicine Department, Weill Cornell Medicine, New York, New York.
Iannis AifantisDepartment of Pathology, Laura and Isaac Perlmutter Cancer Center, and The Helen L. and Martin S. Kimmel Center for Stem Cell Biology, NYU School of Medicine, New York, New York.
Ross L LevineCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Olivier ElementoInstitute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.
Giorgio InghiramiPathology and Laboratory Medicine Department, Weill Cornell Medicine, New York, New York.
Michael R GreenDepartment of Lymphoma/Myeloma and Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maria E FigueroaSylvester Comprehensive Cancer Center, Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, Florida.
Olivier A BernardINSERM U1170, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France. amm2014@med.cornell.edu olivier.bernard@inserm.fr Said.AOUFOUCHI@gustaveroussy.fr sheng.li@jax.org rshaknovich@gmail.com.
Said AoufouchiCNRS UMR8200, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France. amm2014@med.cornell.edu olivier.bernard@inserm.fr Said.AOUFOUCHI@gustaveroussy.fr sheng.li@jax.org rshaknovich@gmail.com.
Sheng LiThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut. amm2014@med.cornell.edu olivier.bernard@inserm.fr Said.AOUFOUCHI@gustaveroussy.fr sheng.li@jax.org rshaknovich@gmail.com.ORCID 0000-0002-9543-6274
Rita ShaknovichDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York. amm2014@med.cornell.edu olivier.bernard@inserm.fr Said.AOUFOUCHI@gustaveroussy.fr sheng.li@jax.org rshaknovich@gmail.com.
Ari M MelnickDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York. amm2014@med.cornell.edu olivier.bernard@inserm.fr Said.AOUFOUCHI@gustaveroussy.fr sheng.li@jax.org rshaknovich@gmail.com.
Cornell University · USInserm · FRCentre National de la Recherche Scientifique · FRJackson Laboratory · USMemorial Sloan Kettering Cancer Center · USNew York University · USSylvester Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Connecticut · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MShared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9MTargeting Epigenetic Circuits in B-Cell LymphomasR35CA220499 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2018 to 2024
$7.2MIdentifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP InactivationR01CA201380 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Richard Green · 2016 to 2026
$3.5MTargeting EZH2 in Germinal Center Derived B-Cell LymphomaR01CA187109 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2014 to 2017
$1.8MAnalysis of TET2 function in acute leukemiaK08CA181507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SHIH, ALAN · 2016 to 2020
$900kCell SorterS10OD019986 · OD · HOSPITAL FOR SPECIAL SURGERY · PI LU, THERESA T. · 2015 to 2015
$600kNCI NIH HHS K08 CA181507NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA034196NCI NIH HHS R01 CA187109NCI NIH HHS R01 CA201380NCI NIH HHS R35 CA220499NIH HHS S10 OD019986
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsCell DifferentiationCREB-Binding ProteinDioxygenasesDNA-Binding ProteinsEpigenesis, GeneticGene Expression ProfilingGerminal CenterHematopoietic Stem CellsHumansHyperplasiaLymphoma, Large B-Cell, DiffuseMice, KnockoutMice, TransgenicMutationPlasma CellsCREB-Binding ProteinCREBBP protein, humanDioxygenasesDNA-Binding ProteinsPositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanProto-Oncogene ProteinsTET2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.